ALEXANDRIA, Va., May 19 -- United States Patent no. 12,629,405, issued on May 19, was assigned to PANTAPHARM AG (Duderstadt, Germany).
"Ezrin peptide 1 for use in a method of treating COVID-19" was invented by Thomas Nesselhut (Duderstadt, Germany), Jan Nesselhut (Duderstadt, Germany) and Rudiger Osmers (Duderstadt, Germany).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to Ezrin peptide 1 and/or an analogue thereof for use in a method of treating COVID-19 and for use in a method of treating post COVID-19 syndrome."
The patent was filed on March 31, 2021, under Application No. 17/915,847.
*For further information, including images, charts and tables, please visit: http://patft....